Imperial College London
Under
the influence of LSD, the brain's visual cortex has increased
connectivity with other brain regions (right) than when imaged under
placebo (left).
Researchers have published the first images
showing the effects of LSD on the human brain, as part of a series of
studies that are examining how the drug causes its characteristic
hallucinogenic effects
1.
David Nutt, a neuropsychopharmacologist at Imperial College London who has
previously examined the neural effects of mind-altering drugs such as the hallucinogen psilocybin — an active ingredient in magic mushrooms — was one of the study's leaders. He tells
Nature what the research revealed, and how LSD (lysergic acid diethylamide) might ultimately be useful in therapies.
Why study the effects of LSD on the brain?
For
brain researchers, studying how psychedelic drugs such as LSD alter the
‘normal’ brain state is a way to study the biological phenomenon that
is consciousness.
We ultimately would also like to see LSD
deployed as a therapeutic tool. The idea has old roots. In the 1950s and
1960s, thousands of people took LSD for alcoholism; in 2012, a
retrospective analysis of some of these studies2
suggested that it helped to cut down on drinking. Since the 1970s,
there have been lots of studies with LSD on animals, but not on the
human brain. We need that data to validate the trial of this drug as a
potential therapy for addiction or depression.
Why hasn’t anyone done brain scans before?
Before
the 1960s, LSD was studied for its potential therapeutic uses, as were
other hallucinogens. But the drug was heavily restricted in the United
Kingdom, the United States and around the world after 1967 — in my view,
due to unfounded hysteria over its potential dangers. The restrictions
vary worldwide, but in general, countries have insisted that LSD has ‘no
medical value’, making it tremendously difficult to work with.
Suzanne Plunkett/REUTERS
David Nutt.
How did you get approval to give volunteers LSD?
United
Nations conventions and national laws do permit academic research on
heavily restricted drugs such as LSD. In the United Kingdom, this sort
of study is legal as long as the drug is not being used as a
therapeutic. This was not a clinical trial: we gave LSD to volunteers
who were already experienced with the drugs and took their brain scans
over eight hours in the lab in Cardiff, UK, in 2014. It took us nine
months to get approval from a
UK ethics committee
for the work: the research was funded by the Safra Foundation [a
philanthropic foundation based in Geneva, Switzerland] and the Beckley
Foundation [a charity near Oxford, UK, that promotes drug-policy
reform], although we needed to
crowdfund through Walacea.com for the resources to analyse the data.
What were the results of the study?
To
take advantage of the “long trip” produced by LSD — an eight-hour
experience, as compared to, say, four on psilocybin — we put our
participants through a huge range of tests.
In one study in the
Proceedings of the National Academy of Sciences,
we looked at blood flow in different parts of the brain using
functional magnetic resonance imaging (fMRI), and at electrical activity
using magnetoencephalography
1.
We found that under LSD, as compared to placebo, disparate regions in
the brain communicate with each other when they don’t normally do so. In
particular, the visual cortex increases its communication with other
areas of the brain, which helps to explain the vivid and complex
hallucinations experienced under LSD, and the emotional flavour they can
take.
On the other hand, within some important brain networks, such as the
neuronal networks that normally fire together when the brain is at rest,
which is sometimes called the ‘default mode’ network, we saw reduced
blood flow — something we’ve also seen with psilocybin — and that
neurons that normally fire together lost synchronization. That
correlated with our volunteers reporting a disintegration of their sense
of self, or ego. This known effect is called ‘ego dissolution’: the
sense that you are less a singular entity, and more melded with people
and things around you. We showed that this could be experienced
independently of the hallucinatory effects — the two don’t necessarily
go together.
What else?
Among
other studies, one of our team, Mendel Kaelen, a PhD student at
Imperial College London, has a paper which will appear next week in
European Neuropsychopharmacology3 looking
at how listening to music affects the experience of taking LSD. He
found that communication between the parahippocampus [a brain region
important in memory storage] and the visual cortex [which processes
information input from the eyes] is reduced when you take LSD. But when
you hear music as well, the visual cortex receives more information from
the parahippocampus, and this is associated with increases in
‘eyes-closed’ imagery and personal memories. So music enhances the LSD
experience and might be important in therapeutic settings.
Another study, to be published in
Current Biology4
and led by Robin Carhart-Harris of Imperial, looks at how ego
dissolution correlates with an increase in global connectivity — all the
parts of the brain communicating with each other to a greater degree.
With
only 20 participants — and only 15 quality data points because 5 people
moved too much inside the brain scanner — how confident can you be in
your findings?
We got very clear and significant effects — and they were consistent with the data from previous studies with psilocybin
4, although the effects with LSD were much stronger.
Are other scientists working with LSD?
We
think there is only one other group in the world currently working with
LSD in humans. They are based at the University of Zurich in
Switzerland, led by Franz Vollenweider. They seem to be focusing on
using antagonists [which block LSD and its effects] to clarify the
pharmacological targets of LSD. They have done their own fMRI scans, but
taken during psychological tasks, rather than when the brain is at
rest, as we did. Their results haven’t been published yet, so I can’t
comment on their findings.
What studies will you do next?
We
have plans to do separate experiments to look at how LSD can influence
creativity, and how the LSD state mimics the dream state.
More importantly, we have already completed
a trial on psilocybin as a therapy for treatment-resistant depression
funded by the UK Medical Research Council: not as a daily drug, but in
targeted psychotherapeutic sessions. Results will be presented next
month. The basic argument for this is that we know that the default-mode
network is overactive in people who are depressed, and we know from our
earlier study
5 that psilocybin reduces how integrated that network is — at least during the ‘trip’ itself.
Our
latest brain-imaging study suggests that LSD has similar effects —
suggesting that it could be trialled therapeutically, too.